Monocyte CD169 Expression as a Biomarker in the Early Diagnosis of Coronavirus Disease 2019
Anne‐Sophie Bedin, Alain Makinson, Marie‐Christine Picot, Frank Mennechet, Fabrice Malergue, Amandine Pisoni, Esperance Nyiramigisha, Lise Montagnier, Karine Bolloré, Ségolène Debiesse, David Morquin, P Bourgoin, Nicolas Veyrenche, Constance Renault, Vincent Foulongne, Caroline Bret, Arnaud Bourdin, Vincent Le Moing, Philippe Van de Perre, Édouard Tuaillon
Abstract
We assessed the expression of CD169, a type I interferon-inducible receptor, on monocytes (monocyte CD169 [mCD169]) in 53 adult patients admitted to the hospital during the coronavirus disease 2019 (COVID-19) outbreak for a suspicion of severe acute respiratory syndrome coronavirus 2 infection. Monocyte CD169 was strongly overexpressed in 30 of 32 (93.7%) confirmed COVID-19 cases, compared with 3 of 21 (14.3%) patients in whom the diagnosis of COVID-19 was finally ruled out. Monocyte CD169 was associated with the plasma interferon-alpha level and thrombocytopenia. Monocyte CD169 testing may be helpful for the rapid triage of suspected COVID-19 patients during an outbreak.